Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $90 from $54 and keeps a Buy rating on the shares. The firm is “encouraged” by the company’s ongoing clinical developments and strong financial position and believes the stock is trading at a significant discount, says the analyst, who updated the firm’s model to reflect GSK‘s (GSK) Jemperli royalties.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio Reports Strong Q1 2025 Results and Progress
- AnaptysBio price target raised to $54 from $52 at Guggenheim
- Hold Rating for AnaptysBio Amid Uncertainties in Clinical Trial Data and Market Position
- AnaptysBio reports Q1 EPS ($1.28), consensus ($1.46)
- Promising Financial Future for AnaptysBio: Buy Rating Justified by Strategic Collaborations and Market Performance
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue